Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC

Phase 1

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Sintilimab
Drug: IBI110
Drug: Paclitaxel
Drug: Cis Platinum
Procedure: Surgery
Radiation: Adjuvant radiation

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06494943

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Cadonilimab
Radiation: Low-dose radiotherapy
Radiation: SBRT
Drug: Capecitabine

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT06494995

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study

Completed

Conditions: Prostate Cancer

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT06484127

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China

Not Applicable

Recruiting

Conditions: Financial Toxicity
Breast Neoplasm Female
Financial Navigation

Interventions: Behavioral: Financial Navigation
Other: Usual Care

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Fudan University

Target Recruit Count: 76

Registration Number: NCT06484140

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Adebrelimab
Drug: Oxaliplatin 100 MG
Drug: Irinotecan liposome
Drug: Calcium Folinate
Drug: Fluorouracil

First Posted Date: 2024-06-26

Last Posted Date: 2024-08-09

Lead Sponsor: Fudan University

Target Recruit Count: 87

Registration Number: NCT06475326

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450

First Posted Date: 2024-06-26

Last Posted Date: 2024-06-26

Lead Sponsor: Fudan University

Target Recruit Count: 42

Registration Number: NCT06475287

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer
Hormone-receptor-positive Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: SHR-A1921
Drug: Adebrelimab

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT06470672

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial

Not Applicable

Not yet recruiting

Conditions: Gastric Cancer
Total Gastrectomy
Follow-up
Postoperative Care
Quality of Life

Interventions: Other: Enhanced Follow-up

First Posted Date: 2024-06-21

Last Posted Date: 2024-06-21

Lead Sponsor: Fudan University

Target Recruit Count: 158

Registration Number: NCT06468969

Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

Phase 2

Recruiting

Conditions: Early Low Rectal Cancer

Interventions: Radiation: Short-course radiotherapy
Radiation: Long-course radiotherapy
Drug: PD-1 antibody (Toripalimab)
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Fudan University

Target Recruit Count: 134

Registration Number: NCT06462053

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Multi-omics Model for Pancreatic Cancer Screening Using cfDNA

Recruiting

Conditions: Pancreatic Cancer

Interventions: Diagnostic Test: A noninvasive cfDNA multi-omics assay

First Posted Date: 2024-06-13

Last Posted Date: 2024-07-01

Lead Sponsor: Fudan University

Target Recruit Count: 480

Registration Number: NCT06456281

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy